Sermorelin — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Sermorelin

Also known as: GHRH(1-29)NH2, hGRF(1-29)NH2, GRF 1-29, Geref, hGHRH(1-29)-NH2, SERM

Growth Hormone-Releasing Hormone (GHRH) analogue; growth hormone secretagogue

Formerly FDA-approvedLast updated: October 31, 2026Based on 17 peer-reviewed studies

What it is

Sermorelin is a peptide people use to stimulate natural growth hormone release for aging-related GH decline, body composition, and recovery. It works by activating the same pituitary receptor as the natural hormone that triggers GH pulses. Previously FDA-approved; now only available through compounding; banned by WADA in sport.

The scientific side

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal active fragment of endogenous hypothalamic growth hormone-releasing hormone (GHRH). It binds to and activates the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, stimulating the secretion of endogenous growth hormone (GH), which in turn elevates circulating insulin-like growth factor-1 (IGF-1) levels. The peptide's plasma half-life is approximately 10–20 minutes in humans, limited primarily by renal ultrafiltration and enzymatic N-terminal degradation. Beyond pituitary actions, the GHRH receptor and its splice variants are expressed in multiple extrapituitary tissues including cancer cell lines, cardiac myocytes, retinal cells, corneal endothelium, and immune cells; activation or antagonism of this receptor modulates proliferation, apoptosis, inflammation, and redox signalling through pathways including cAMP/PKA, MAPK/ERK, JAK/STAT3, NF-κB, and HIF-1α.

Class: Growth Hormone-Releasing Hormone (GHRH) analogue; growth hormone secretagogue

Formerly FDA-approvedModerate researchHormonesGHRH analog

At a glance

What it isA synthetic copy of the first 29 amino acids of growth hormone-releasing hormone (GHRH 1-29), the shortest piece that keeps full activity.
FDA statusNot currently approved. It was approved as Geref (1990 and 1997); the maker discontinued it in 2008, and FDA later found that was not for safety or effectiveness reasons.
Used forFormerly growth hormone deficiency in children; now mostly anti-aging and sleep clinics, often compounded.
Human evidenceA 110-child trial behind its approval, plus small, short trials in older adults.
Half-lifeAbout 10-20 minutes in humans, which is why it is usually injected at bedtime.
Banned in sportYes. WADA names it under S2.2.4 (growth hormone releasing factors), prohibited at all times.

What is Sermorelin?

Sermorelin is a synthetic peptide matching the first 29 amino acids of human growth hormone-releasing hormone, the signal the brain sends to the pituitary to release growth hormone. It is the shortest fragment that keeps full activity, also written as GHRH(1-29)-NH2.

It is related to Tesamorelin, which uses the full 44-amino-acid sequence with a stabilizing group, and to Mod GRF 1-29 and CJC-1295, which modify the same 29-amino-acid sequence to make it last longer.

Sources: [1] [2]

How does it work?

Sermorelin binds GHRH receptors on the pituitary, which releases the body's own growth hormone in a pulse. Because it works upstream, the response stays subject to the body's normal feedback controls, unlike injected growth hormone.

It is cleared within minutes, but the growth hormone response lasts longer: after IV doses in healthy men, growth hormone stayed elevated for about 3 hours. Bedtime injections aim to line this pulse up with the body's natural growth hormone release in early sleep.

Pharmacokinetics

Half-lifeAbout 10-20 minutes in humans
MetabolismBroken down mainly by enzymes cleaving the N-terminus
ClearanceMostly renal ultrafiltration
RouteInjection under the skin, usually at bedtime; intranasal bioavailability was only 3-5%

Sources: [3] [2]

Is it FDA-approved?

Not anymore. FDA approved sermorelin as Geref in 1990 to test pituitary growth hormone release, and in 1997 to treat children with idiopathic growth hormone deficiency. The maker, EMD Serono, discontinued both in 2008.

In 2013, FDA formally determined that Geref "was not withdrawn from sale for reasons of safety or effectiveness", which allows generic versions to be approved. None is currently marketed. FDA's list of compounding substances with significant safety risks does not name sermorelin.

  • Formerly FDA-approved as: Geref (approved 1990; discontinued 2008)
  • Why it was discontinued: Not withdrawn from sale for reasons of safety or effectiveness (FDA, 2013) Source
  • WADA: S2.2.4 Growth hormone releasing factors (named among GHRH analogues; prohibited at all times)

Sources: [4] [5] [6] [7]

History

Growth hormone-releasing hormone was isolated in 1982 from a human pancreatic tumor that had caused acromegaly. The first 29 amino acids turned out to carry its activity, and that fragment became sermorelin.

Serono developed it as Geref. A 110-child trial showed once-daily bedtime injections roughly doubled growth rates in children with growth hormone deficiency, and FDA approved the treatment form in 1997. With recombinant growth hormone dominating the market, Serono discontinued Geref in 2008. Sermorelin has since returned as a compounded "anti-aging" peptide.

Sources: [8] [1] [9] [6]

Regulatory timeline

  1. December 28, 1990FDA approves Geref (sermorelin acetate) 0.05 mg to test the pituitary's ability to release growth hormone. Source
  2. September 26, 1997FDA approves Geref 0.5 mg and 1 mg vials to treat idiopathic growth hormone deficiency in children with growth failure. Source
  3. 2008EMD Serono notifies FDA that both Geref products are being discontinued (letters dated July 11 and December 2, 2008). Source
  4. March 4, 2013FDA determines Geref was not withdrawn from sale for reasons of safety or effectiveness. Source
  5. As of April 2026FDA's list of compounding substances with significant safety risks does not name sermorelin. Source

Side effects

In the trials behind its approval, sermorelin was well tolerated. Transient facial flushing and pain at the injection site were the most commonly reported adverse events. The 110-child trial found no adverse changes in blood chemistry or hormones, no change in fasting glucose and no excess IGF-1.

In older adults, a 6-week trial of 2 mg nightly reported no significant adverse effects. Long-term safety in adults using it for anti-aging has not been studied.

Common

  • Facial flushing (transient)
  • Pain at the injection site

Who should not use it

  • No current label: the former Geref labeling is no longer in effect.
  • Competitive athletes: prohibited at all times under WADA S2.2.4.
  • Active cancer: it raises growth hormone and IGF-1, growth factors that approved GH-releasing drugs list as a contraindication.
  • Pregnancy and breastfeeding: not studied in adults using it off-label.

Most commonly reported adverse events in the Geref trials, per the 1999 BioDrugs review; trials reported no serious drug-related events.

Sources: [1] [9] [10]

What does the research show?

In children with growth hormone deficiency, 30 micrograms/kg at bedtime raised height velocity from 4.1 to 8.0 cm per year at 6 months. Over time it worked less well than daily growth hormone injections.

In older men, 1 mg twice daily for 14 days restored growth hormone and IGF-1 toward young-adult levels. A single 2 mg nightly dose for 6 weeks raised night-time growth hormone but did not change IGF-1 or body composition; the authors concluded single nightly doses are less effective than multiple daily doses.

Two often-cited 1997 studies in older adults reported higher IGF-1 and lean mass, but they used [Nle27]GHRH(1-29), a modified version, not sermorelin itself.

Studied for

  • Growth hormone deficiency in children (approved as Geref 1997-2008)
  • Diagnosis of growth hormone deficiency (approved as Geref 1990-2008)
  • Growth hormone and IGF-1 decline in older adults (small, short trials)

Sources: [9] [1] [11] [10] [12]

FAQ

Was Sermorelin ever FDA-approved?

Yes. As Geref, it was approved in 1990 for diagnosis and in 1997 to treat growth hormone deficiency in children. It was discontinued in 2008.

Sources: [4] [5]

Was Geref pulled because it was unsafe?

No. In 2013 FDA determined Geref "was not withdrawn from sale for reasons of safety or effectiveness".

Sources: [6]

Is Sermorelin the same as growth hormone?

No. It signals the pituitary to release your own growth hormone, so the response stays under the body's normal feedback controls.

Sources: [1]

Why is Sermorelin taken at bedtime?

Its half-life is about 10-20 minutes, so each dose produces a short growth hormone pulse. Bedtime dosing lines that pulse up with the body's natural release in early sleep; the Geref pediatric trial dosed at bedtime.

Sources: [2] [9]

Does Sermorelin raise IGF-1 in adults?

In one 14-day trial, 1 mg twice daily did. A single 2 mg nightly dose for 6 weeks did not.

Sources: [11] [10]

Is Sermorelin on FDA's compounding risk list?

No. FDA's list of compounding substances with significant safety risks does not name sermorelin.

Sources: [7]

Is Sermorelin banned in sport?

Yes. The 2026 WADA Prohibited List names sermorelin under S2.2.4, prohibited at all times.

Sources: [13]

Citations

  1. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999. PMID 18031173
  2. Esposito P, et al. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev 2003. PMID 14499707
  3. Wilton P, et al. Pharmacokinetics of GHRH(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl 1993. PMID 8329825
  4. Drugs@FDA: NDA 019863, Geref (sermorelin acetate) 0.05 mg/amp. accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019863
  5. Drugs@FDA: NDA 020443, Geref (sermorelin acetate) 0.5 and 1 mg/vial. accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443
  6. FDA: Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness. Federal Register, March 4, 2013. federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams
  7. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  8. Guillemin R, et al. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982. PMID 6812220
  9. Thorner M; Geref International Study Group. Once daily subcutaneous GHRH therapy accelerates growth in GH-deficient children during the first year of therapy. J Clin Endocrinol Metab 1996. PMID 8772599
  10. Vittone J, et al. Effects of single nightly injections of GHRH (1-29) in healthy elderly men. Metabolism 1997. PMID 9005976
  11. Corpas E, et al. GHRH-(1-29) twice daily reverses the decreased GH and IGF-I levels in old men. J Clin Endocrinol Metab 1992. PMID 1379256
  12. Khorram O, et al. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997. PMID 9141536
  13. World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf

Sources

Administration & storage

Administration
Subcutaneous injection — human volunteer pharmacokinetic study (PMID: 26879649)Intravenous injection — diagnostic GH stimulation studies in humans (PMID: 105945209543138)Subcutaneous injection — animal (rat/pig) PEGylation pharmacodynamic studies (PMID: 14499707)
Storage
No storage conditions for sermorelin are described in the reviewed abstracts.
Cautions
Sermorelin's short plasma half-life (~10–20 min in humans) is caused by renal ultrafiltration and enzymatic N-terminal degradation; rapid elimination complicates pharmacodynamic management.,A case report associates long-term cyclical use of sermorelin/GHRP-6 combination therapy over approximately 20 years with anterior cervical osteophyte formation and dysphagia in a single patient; causality was not established.,Reported adverse effects associated with GH-axis modulating peptides in self-administration contexts include endocrine/metabolic disturbances (prolactin and cortisol elevations, appetite changes, dysglycaemia), fluid retention, myalgia/arthralgia, and injection-site reactions.,Products obtained from unregulated (gray-market) sources are frequently mislabeled or contaminated; falsified biopharmaceutical injectables including sermorelin have been seized in European anti-counterfeiting operations.,Potential for serious harm exists; rigorous human safety data are scarce for off-label and performance-enhancement uses.,Sterile technique is required for all injectable peptides to prevent injection-site infection and systemic contamination.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Prohibited. GHRH and its synthetic analogues (including sermorelin) are prohibited by the World Anti-Doping Agency (WADA). Multiple anti-doping detection methods have been developed and validated to WADA requirements.

Health Canada

Not stated in reviewed literature — requires manual verification